相关实验视频
Updated: Jun 26, 2025

08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.1K
在对abrocitinib诱导反应的患者中优化维护疗法:对JADE REGIMEN的后期分析
J P Thyssen1, J I Silverberg2, J Ruano3
1Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark.
概括
降低剂量的abrocitinib (100mg) 可以维持治疗响应中度至严重的亚托皮炎 (AD) 患者的治疗反应,这些患者的基线疾病严重程度较低,并且对初始abrocitinib (200mg) 诱导疗法反应良好.
科学领域:
- 皮肤病学 皮肤病学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 在JADE REGIMEN试验中,研究了abrocitinib治疗中度至重度的亚托皮性皮炎 (AD).
- 剂量灵活性对于优化AD治疗结果至关重要.
- 持续剂量abrocitinib (200毫克) 在维持期间显示出更强的爆发预防,但比降低剂量 (100毫克) 更多的不良事件.
研究的目的:
- 为了确定在阿布罗西提尼布维持治疗期间保持无发作的预测因素.
- 开发工具来评估不经历疾病爆发的可能性.
主要方法:
- 对 JADE REGIMEN 试验数据的后期分析.
- 后勤回归用于识别未燃烧的预测因素.
- 开发的多变量回归模型,以评估基于显著预测因素的不燃烧的概率.
主要成果:
- 不燃烧的预测因素包括基线下部受影响的身体表面积,没有先前的全身药物使用,以及比基线更大的EASI得分降低.
- 从基线到第12周的湿疹区域和严重性指数 (EASI) 的百分比变化是维持期间不燃烧的关键预测指标.
结论:
- 降低剂量abrocitinib (100毫克) 维护可能是选择AD患者的可行选择.
- 可行性与较低的基线疾病严重程度和对200毫克诱导疗法的强有力的反应有关.
更多相关视频
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.5K
12:40A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
14.9K
相关概念视频
The JAK-STAT Signaling Pathway
8.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.8K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K